Medivir AB And County Councils Conclude Agreement On Olysio®-Based Treatment For Hepatitis C

HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir AB (STO:MVIR-B) announces that the company has entered into an agreement with Swedish county councils regarding the treatment of hepatitis C with Olysio® (simeprevir). The Dental and Pharmaceutical Benefits Agency (TLV) has concluded that treatment with Olysio® (simeprevir) is beneficial from a health economics viewpoint in the treatment of HCV genotypes 1 and 4 with METAVIR scores of F3-F4, irrespective of previous treatment.

Help employers find you! Check out all the jobs and post your resume.